Furthermore, all data derived from large RCTs showed that treatment with SGLT2 inhibitors had a safe and neutral effect on the risk of stroke, with a potential beneficial effect on hemorrhagic stroke over placebo. The gene discussed is SLC5A2; the disease is stroke disorder.